Decheng Capital as of March 31, 2026
Portfolio Holdings for Decheng Capital
Decheng Capital holds 14 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Cg Oncology (CGON) | 65.2 | $431M | 6.4M | 67.68 | |
| Nuvation Bio (NUVB) | 16.8 | $111M | 26M | 4.29 | |
| Upstream Bio (UPB) | 3.7 | $25M | 2.7M | 9.00 | |
| Aclaris Therapeutics (ACRS) | 2.3 | $15M | 4.0M | 3.75 | |
| Aardvark Therapeutics (AARD) | 2.2 | $15M | 3.9M | 3.77 | |
| Lyell Immunopharma | 2.1 | $14M | 692k | 20.06 | |
| Newamsterdam Pharma Co Nv (NAMS) | 1.6 | $10M | 325k | 32.01 | |
| Arcus Biosciences Incorporated (RCUS) | 1.6 | $10M | 478k | 21.60 | |
| Revolution Medicines (RVMD) | 1.4 | $9.1M | 94k | 97.25 | |
| Equillium (EQ) | 1.3 | $8.9M | 4.4M | 2.00 | |
| BeyondSpring SHS (BYSI) | 0.9 | $6.2M | 3.8M | 1.64 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.5 | $3.1M | 1.3M | 2.34 | |
| Krystal Biotech (KRYS) | 0.3 | $1.9M | 7.3k | 258.32 | |
| Pyxis Oncology (PYXS) | 0.1 | $477k | 327k | 1.46 |
